US20020019357A1 - Use of magnesium (mg2+) for the preparation of a therapeutic composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy - Google Patents
Use of magnesium (mg2+) for the preparation of a therapeutic composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy Download PDFInfo
- Publication number
- US20020019357A1 US20020019357A1 US09/408,947 US40894799A US2002019357A1 US 20020019357 A1 US20020019357 A1 US 20020019357A1 US 40894799 A US40894799 A US 40894799A US 2002019357 A1 US2002019357 A1 US 2002019357A1
- Authority
- US
- United States
- Prior art keywords
- polynucleotide
- magnesium
- administration
- cells
- therapeutic composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108091033319 polynucleotide Proteins 0.000 title claims abstract description 65
- 102000040430 polynucleotide Human genes 0.000 title claims abstract description 65
- 239000002157 polynucleotide Substances 0.000 title claims abstract description 65
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 229910052749 magnesium Inorganic materials 0.000 title claims abstract description 35
- 239000011777 magnesium Substances 0.000 title claims abstract description 35
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 title claims abstract description 34
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 238000001890 transfection Methods 0.000 title claims description 17
- 238000001415 gene therapy Methods 0.000 title description 17
- 238000001727 in vivo Methods 0.000 claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 24
- 229920001184 polypeptide Polymers 0.000 claims description 23
- 210000003205 muscle Anatomy 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- 210000001519 tissue Anatomy 0.000 claims description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 claims description 5
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 claims description 5
- 108010069091 Dystrophin Proteins 0.000 claims description 5
- 238000007918 intramuscular administration Methods 0.000 claims description 5
- 102000001039 Dystrophin Human genes 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical group [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 3
- 125000002091 cationic group Chemical group 0.000 claims description 3
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims description 2
- AVQQQNCBBIEMEU-UHFFFAOYSA-N 1,1,3,3-tetramethylurea Chemical compound CN(C)C(=O)N(C)C AVQQQNCBBIEMEU-UHFFFAOYSA-N 0.000 claims description 2
- BQCCJWMQESHLIT-UHFFFAOYSA-N 1-propylsulfinylpropane Chemical compound CCCS(=O)CCC BQCCJWMQESHLIT-UHFFFAOYSA-N 0.000 claims description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 229960003677 chloroquine Drugs 0.000 claims description 2
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims description 2
- CCAFPWNGIUBUSD-UHFFFAOYSA-N diethyl sulfoxide Chemical compound CCS(=O)CC CCAFPWNGIUBUSD-UHFFFAOYSA-N 0.000 claims description 2
- 238000001361 intraarterial administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 230000002601 intratumoral effect Effects 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 39
- 239000013612 plasmid Substances 0.000 description 14
- 238000012384 transportation and delivery Methods 0.000 description 14
- 108060001084 Luciferase Proteins 0.000 description 13
- 239000005089 Luciferase Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 239000001110 calcium chloride Substances 0.000 description 7
- 229910001628 calcium chloride Inorganic materials 0.000 description 7
- 210000000663 muscle cell Anatomy 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 201000003883 Cystic fibrosis Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 108090000994 Catalytic RNA Proteins 0.000 description 3
- 102000053642 Catalytic RNA Human genes 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 108091092562 ribozyme Proteins 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- VLEIUWBSEKKKFX-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O VLEIUWBSEKKKFX-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 150000001767 cationic compounds Chemical class 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- -1 for example Chemical class 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 229940076144 interleukin-10 Drugs 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 201000006938 muscular dystrophy Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- WALUVDCNGPQPOD-UHFFFAOYSA-M 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC WALUVDCNGPQPOD-UHFFFAOYSA-M 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 201000006935 Becker muscular dystrophy Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 101710117545 C protein Proteins 0.000 description 1
- 101150029409 CFTR gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 101000783356 Naja sputatrix Cytotoxin Proteins 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 101150003725 TK gene Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 241001441550 Zeiformes Species 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 210000005058 airway cell Anatomy 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002340 cardiotoxin Substances 0.000 description 1
- 231100000677 cardiotoxin Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical compound [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000006674 lysosomal degradation Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 238000001964 muscle biopsy Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920000962 poly(amidoamine) Polymers 0.000 description 1
- 229920000333 poly(propyleneimine) Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to the use of magnesium (Mg 2+ ) for the preparation of a therapeutic composition for improving transfection of a polynucleotide into a cell.
- a therapeutic composition for improving transfection of a polynucleotide into a cell.
- Such a composition is useful in gene therapy, vaccination, and any therapeutic or prophylactic situation in which a gene-based product is administered to cells in vivo.
- Gene therapy has generally been conceived as principally applicable to heritable deficiency diseases (cystic fibrosis, dystrophies, haemophilias, etc.) where permanent cure may be effected by introducing a functional gene.
- heritable deficiency diseases cystic fibrosis, dystrophies, haemophilias, etc.
- permanent cure may be effected by introducing a functional gene.
- a much larger group of diseases notably acquired diseases (cancer, AIDS, multiple sclerosis, etc.) might be treatable by transiently engineering host cells to produce beneficial proteins.
- the immunogenic product encoded by the polynucleotide introduced in cells of a vertebrate may be expressed and secreted or be presented by said cells in the context of the major histocompatibility antigens, thereby eliciting an immune response against the expressed immunogen.
- Functional polynucleotides can be introduced into cells by a variety of techniques resulting in either transient expression of the gene of interest, referred to as transient transfection, or permanent transformation of the host cells resulting from incorporation of the polynucleotide into the host genome.
- Successful gene therapy depends on the efficient delivery to and expression of genetic information within the cells of a living organism.
- Viruses have developed diverse and highly sophisticated mechanisms to achieve this goal including crossing of the cellular membrane, escape from lysosomal degradation, delivery of their genome to the nucleus and, consequently, have been used in many gene delivery applications in vaccination or gene therapy applied to humans.
- retroviral vectors cannot accommodate large-sized DNA (for example, the dystrophin gene which is around 13 Kb), the retroviral genome is integrated into host cell DNA and may thus cause genetic changes in the recipient cell and infectious viral particles could disseminate in the organism or in the environment and adenoviral vectors can induce a strong immune response in treated patients (Mc Coy et al., Human Gene Therapy 6 (1995), 1553-1560; Yang et al., Immunity 1 (1996), 433-442). Nevertheless, despite these drawbacks, viral vectors are currently the most useful delivery systems because of their efficiency.
- Non-viral delivery systems have been developed which are based on receptor-mediated mechanisms (Perales et al., Eur. J. Biochem. 226 (1994), 255-266; Wagner et al., Advanced Drug Delivery Reviews 14 (1994), 113-135), on polymer-mediated transfection such as polyamidoamine (Haensler and Szoka, Bioconjugate Chem. 4 (1993), 372-379), dendritic polymer (WO 95/24221), polyethylene imine or polypropylene imine (WO 96/02655), polylysine (U.S. Pat. No.
- the technical problem underlying the present invention is the provision of improved methods and means for the delivery of nucleic acid molecules in gene therapy.
- the present invention relates to the use of magnesium (Mg 2+ ) for the preparation of a therapeutic composition for transfecting a polynucleotide into a cell in vivo. It was surprisingly found that the specific addition of magnesium when transfecting a polynucleotide into vertebrate tissue leads to a dramatic improvement of the transfection efficiency. Thus, the present invention preferably relates to the use of magnesium (Mg 2+ ) for the preparation of a pharmaceutical composition for an improved transfection of a polynucleotide into a cell.
- improved transfection in the scope of the present invention means, in this regard, a more efficient uptake of a polynucleotide by cells when magnesium (Mg 2+ ) is present compared to an introduction performed without magnesium. This can be determined by comparing the amount of the polynucleotide taken up without the use of magnesium and comparing this amount with the amount taken up by the cells when using magnesium under the same experimental conditions. Preferably, the improved transfection can be determined by a higher amount of expression of the polynucleotide transferred into the cells when using magnesium (Mg 2+ ) in comparison to a situation where no magnesium (Mg 2+ ) is used.
- compositions prepared according to the use of the present invention are particularly useful for the delivery of polynucleotides to cells or tissues of a subject in the scope of a gene therapeutic method but are not limited to such use.
- the term “gene therapy method” is preferably understood as a method for the transfection of a polynucleotide into cells in vivo. “Gene therapy” in particular concerns the case where the gene product is expressed in a target tissue as well as the case where the gene product is excreted, especially into the blood stream.
- transfection means the transfer of the polynucleotide into a cell wherein the polynucleotide is not associated with viral particles.
- transfection is to be distinguished from infection which relates to polynucleotides associated with viral particles.
- Magnesium (Mg 2+ ) has been shown to:
- [0018] act as a cofactor for the binding of the C protein to its specific site in DNA (De et al., Biochemistry 37 (1998), 3831-8) or of the EcoRV restriction endonuclease (Thielking et al., Biochemistry 31 (1992), 3727-32).
- Japanese patent application (JO8308573) abstract discloses an in vitro method of introducing a gene into cells by using a virus as vector, prepared in a virus-infection medium which contains serum-free ingredients or divalent metal ions selected from Mg, Ca and Zn combined with a cell culture medium based on amino acids.
- magnesium (Mg 2+ ) means the divalent cation of magnesium.
- Such a product is commercially available associated with one or several biologically acceptable anions, such as, for example, bisulfite, chromate, fluoride, gluconate, acetate, hydroxide, iodide, methoxide, oxide, phosphate, sulfate, chloride, bromide, etc (see Aldrich catalogue, 1994/1995, for example).
- said magnesium (Mg 2+ ) is associated with chloride (MgCl 2 ).
- the amount of magnesium in the compositions prepared according to the use of the present invention ranges between about 0.1 to about 100 mM, preferably from about 0.1 to about 10 mM of magnesium, and still preferably is 0.5 mM.
- This concentration may also be adapted by those skilled in the art in particular cases where magnesium concentration can be affected.
- the therapeutic composition further comprises chelating agent, such as EDTA
- the therapeutic composition prepared according to the use of the present invention is in a form for administration into a vertebrate tissue.
- tissues include those of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, connective tissue, blood, tumor etc.
- Cells where the improved transfection of a foreign polynucleotide would be obtained are those found in each of the listed target tissues (muscular cells, airway cells, hematopo ⁇ etic cells, etc.).
- the administration may be made by intradermal, subdermal, intravenous, intramuscular, intranasal, intracerebral, intratracheal, intraarterial, intraperitoneal, intravesical, intrapleural, intracoronary or intratumoral injection, with a syringe or other devices.
- Transdermal administration is also contemplated, as are inhalation or aerosol administration.
- the therapeutic composition prepared according to the use is for the introduction into muscle tissue, more preferably, by intramuscular injection routes.
- the invention provides the use of magnesium for the preparation of a therapeutic composition for improving transfection of a polynucleotide into a cell wherein said therapeutic composition is administered independently from a second administration consisting in administration of a composition containing at least one polynucleotide.
- the first administration can be done prior to, concurrently with or subsequent to the second administration, and vice-versa.
- the therapeutic composition administration and second administration can be performed by different or identical delivery routes (systemic delivery and targeted delivery, or targeted deliveries for example). In a preferred embodiment, each should be done into the same target tissue and most preferably by injection.
- the therapeutic composition further comprises at least one polynucleotide.
- the polynucleotide which is contained in the composition contains and is capable of functionally expressing a gene in said cell.
- the polynucleotide may be a DNA or RNA, single or double stranded, linear or circular, natural or synthetic, modified or not (see U.S. Pat. No. 5,525,711, U.S. Pat. No. 4,711,955 or EP-A 302 175 for modification examples).
- polynucleotide may also be in the form of a plasmid or linear polynucleotide which contains at least one expressible sequence of nucleic acid that can generate a polypeptide, a ribozyme, an antisense RNA or another molecule of interest upon delivery to a cell.
- the polynucleotide can also be an oligonucleotide which is to be delivered to the cell, e.g., for antisense or ribozyme functions.
- the polynucleotide is a naked polynucleotide (Wolff et al., Science 247 (1990), 1465-1468) or is a polynucleotide associated or complexed with a polypeptide, with the proviso that when said polypeptide is a viral polypeptide, then said polynucleotide combined with the viral polypeptide does not form infectious viral particles, or with a cationic compound or with any component which can participate in the protection and uptake of the polynucleotide into the cells (see Ledley, Human Gene Therapy 6 (1995), 1129-1144 for a review).
- Cationic compounds to which the polynucleotide is complexed are preferably cationic lipids, especially those disclosed in WO 98/34910. Both DNA or RNA can be delivered to cells to form therein a polypeptide of interest.
- the polynucleotide present in the therapeutic composition is in the form of plasmid DNA. If the polynucleotide contains the proper genetic information, it will direct the synthesis of relatively large amounts of the encoded polypeptide.
- the use according to the invention can be applied to achieve improved and effective immunity against infectious agents, including intracellular viruses, and also against tumor cells.
- the genetic informations necessary for expression by a target cell comprise all the elements required for transcription of said DNA into mRNA and for translation of mRNA into polypeptide.
- Transcriptional promoters suitable for use in various vertebrate systems are well known.
- suitable promoters include viral promoters like RSV, MPSV, SV40, CMV or 7.5 k, vaccinia promoter, inducible promoters, etc.
- the polynucleotide can also include intron sequences, targeting sequences, transport sequences, sequences involved in replication or integration. Said sequences have been reported in the literature and can be readily obtained by those skilled in the art.
- the polynucleotide can also be modified in order to be stabilized with specific components as spermine.
- the concentration of the polynucleotide in the composition is from about 0.1 ⁇ g/ml to about 20 mg/ml.
- the polynucleotide can be homologous or heterologous to the target cells into which it is introduced.
- said polynucleotide encodes all or part of a polypeptide, especially a therapeutic or prophylactic polypeptide.
- a polypeptide is understood to be any translational product of a polynucleotide regardless of size, and whether glycosylated or not, and includes peptides and proteins.
- Therapeutic polypeptides include as a primary example those polypeptides that can compensate for defective or deficient proteins in an animal or human organism, or those that act through toxic effects to limit or remove harmful cells from the body. They can also be immunity conferring polypeptides which act as endogenous immunogens to provoke a humoral or cellular response, or both.
- polypeptides encoded by the polynucleotide are enzymes, hormones, cytokines, membrane receptors, structural polypeptides, transport polypeptides, adhesines, ligands, transcription factors, transtion factors, replication factors, stabilization factors, antibodies, more especially CFTR, dystrophin, factors VIII or IX, E6 or E7 from HPV, MUC1, BRCA1, interferons, interleukin (IL-2, IL-4, IL-6, IL-7, IL-12, GM-CSF (Granulocyte Macrophage Colony Stimulating Factor), the tk gene from Herpes Simplex type 1 virus (HSV-1), p53 or VEGF.
- HSV-1 Herpes Simplex type 1 virus
- the polynucleotide can also code for an antibody.
- antibody encompasses whole immunoglobulins of any class, chimeric antibodies and hybrid antibodies with dual or multiple antigen or epitope specificities, and fragments, such as F(ab) 2 , Fab', Fab including hybrid fragments and anti-idiotypes (U.S. Pat. No. 4,699,880).
- the composition further comprises at least one component selected from the group consisting of chloroquine, protic compounds such as propylene glycol, polyethylene glycol, glycerol, ethanol, 1-methyl L-2-pyrrolidone or derivatives thereof, aprotic compounds such as dimethylsulfoxide (DMSO), diethylsulfoxide, di-n-propylsulfoxide, dimethylsulfone, sulfolane, dimethylformamide, dimethylacetamide, tetramethylurea, acetonitrile or derivatives.
- Said composition can also comprises at least one component selected from the group consisting of cytokines, especially interleukin-10 (IL-10), and nuclease inhibitors such as, for example, actin G.
- cytokines especially interleukin-10 (IL-10)
- IL-10 interleukin-10
- nuclease inhibitors such as, for example, actin G.
- the composition prepared according to the use of the invention can be used in a method for the therapeutic treatment of humans or animals.
- the composition may also comprise a pharmaceutically acceptable injectable carrier (for examples, see Remington's Pharmaceutical Sciences, 16 th ed. 1980, Mack Publishing Co).
- the carrier is preferably isotonic, hypotonic or weakly hypertonic and has a relatively low ionic strength, such as provided by a sucrose solution.
- aqueous or partly aqueous liquid carriers comprising sterile, pyrogen-free water, dispersion media, coatings, and equivalents, or diluents (e.g;, Tris-HCl, acetate, phosphate), emulsifiers, solubilizers or adjuvants.
- diluents e.g;, Tris-HCl, acetate, phosphate
- emulsifiers emulsifiers
- solubilizers or adjuvants e.g., solubilizers or adjuvants.
- the pH of the pharmaceutical preparation is suitably adjusted and buffered in order to be useful in in vivo applications.
- the present invention also relates to a process for transfecting a polynucleotide into cells wherein said process comprises contacting said cells with a composition prepared according to the use of the invention before, simultaneously or after contacting them with the polynucleotide.
- This process may be applied by direct administration of said composition to cells of the animal in vivo.
- targeted “cells” and “in vivo administration route” are defined as above described.
- muscle is used as a site for the delivery and expression of a polynucleotide in a number of therapeutic applications because animals have a proportionately large muscle mass which is conveniently accessed by direct injection through the skin.
- the invention concerns a process for introducing a polynucleotide, preferably in naked form, into muscle cells in vivo, comprising the steps of administering in vivo at least a polynucleotide and magnesium , preferably intramuscularly, whereby the polynucleotide is introduced into muscle cells of the tissue.
- the polynucleotide may encode a therapeutic polypeptide that is expressed by the muscle cells and eventually secreted into the blood stream after the contacting step to provide therapy to the vertebrate. Similarly, it may encode an immunogenic polypeptide that is expressed by the muscle cells after the contacting step and which generates an immune response, thereby immunizing the vertebrate.
- One important aspect of the invention is a process for the treatment of muscular dystrophy wherein said polynucleotide operatively codes for dystrophin.
- the composition is introduced into the muscle tissue.
- the present invention relates to the use of Magnesium (Mg 2+ ) for improving transfection of a polynucleotide into a cell.
- FIG. 1 shows the opposing effects of CaCl 2 and MgCl 2 on intramuscular transfection of pTG11033.
- Luciferase activity of mouse right and left tibialis anterior muscles measured 7 days after injection with 25 ⁇ g plasmid added with NaCl 0.9% buffer (Control, NaCl) or with either 0.1 to 100 mM of CaCl 2 or 100 mM MgCl 2 .
- Bars are means of RLU (Relative Light Unit) per minute per mg protein +/ ⁇ s.e.m. of 6_determinations.
- FIGS. 2 and 3 show the MgCl 2 dose-effect on intramuscular transfer of the luciferase-plasmid (pTG11033). Bars are means of RLU per minute per mg protein +/ ⁇ s.e.m of 6 determinations. Luciferase activity was measured 7 days after injection of 25 ⁇ g plasmid into C57BL/10 mice (4 mice per group) added with either NaCl 0.9% (empty bars) or different concentrations of MgCl 2 (black bars).
- mice were killed and the tibialis anterior muscles were retrieved and frozen.
- Luciferase activity was quantified on whole muscle extracts using a conventional measurement kit (Luciferase Assay System, Promega). Briefly, muscles were ground separately and diluted in 200 ⁇ l of reporter lysis buffer (Promega). 10 ⁇ l-samples were placed in 96 well-plates and mixed with 100 ⁇ l of substrate. Luciferase activity was expressed as number of RLU emitted per minute, per mg of protein.
- the stock solution of plasmid pTG11033 was prepared in TE buffer (Tris 10 mM-EDTA 1 mM) at a nucleic acid concentration of 1 ⁇ g/ ⁇ l.
- the plasmid pTG11033 was prepared in NaCl 0.9% and stocked at 1 ⁇ g/ ⁇ l. Serial dilution of MgCl 2 solution were prepared in NaCl 0.9% and added to the stock pTG11033 in a final volume of 30 ⁇ l. The control contained the same quantity of the plasmid added with 5 ⁇ l of NaCl 0.9%. Ionic strength of MgCl 2 solutions was balanced with appropriate volumes of water according to methods well known to the person skilled in the art.
Abstract
Description
- The present invention relates to the use of magnesium (Mg2+) for the preparation of a therapeutic composition for improving transfection of a polynucleotide into a cell. Such a composition is useful in gene therapy, vaccination, and any therapeutic or prophylactic situation in which a gene-based product is administered to cells in vivo.
- Gene therapy has generally been conceived as principally applicable to heritable deficiency diseases (cystic fibrosis, dystrophies, haemophilias, etc.) where permanent cure may be effected by introducing a functional gene. However, a much larger group of diseases, notably acquired diseases (cancer, AIDS, multiple sclerosis, etc.) might be treatable by transiently engineering host cells to produce beneficial proteins.
- Applications are, for example, the treatment of muscular dystrophies or of cystic fibrosis. The genes of Duchenne/Becker muscular dystrophy and cystic fibrosis have been identified and encode polypeptides termed dystrophin and cystic fibrosis transmembrane conductance regulator (CFTR), respectively. Direct expression of these genes within, respectively, the muscle or lung cells of patients should contribute to a significant amelioration of the symptoms by expression of the functional polypeptide in targeted tissues. Moreover, in cystic fibrosis studies have suggested that one would need to achieve expression of the CFTR gene product in only about 5% of lung epithelial cells in order to significantly improve the pulmonary symptoms.
- Another application of gene therapy is vaccination. In this regard, the immunogenic product encoded by the polynucleotide introduced in cells of a vertebrate may be expressed and secreted or be presented by said cells in the context of the major histocompatibility antigens, thereby eliciting an immune response against the expressed immunogen. Functional polynucleotides can be introduced into cells by a variety of techniques resulting in either transient expression of the gene of interest, referred to as transient transfection, or permanent transformation of the host cells resulting from incorporation of the polynucleotide into the host genome. Successful gene therapy depends on the efficient delivery to and expression of genetic information within the cells of a living organism. Most delivery mechanisms used to date involve viral vectors, especially adeno- and retroviral vectors. Viruses have developed diverse and highly sophisticated mechanisms to achieve this goal including crossing of the cellular membrane, escape from lysosomal degradation, delivery of their genome to the nucleus and, consequently, have been used in many gene delivery applications in vaccination or gene therapy applied to humans. The use of viruses suffers from a number of disadvantages: retroviral vectors cannot accommodate large-sized DNA (for example, the dystrophin gene which is around 13 Kb), the retroviral genome is integrated into host cell DNA and may thus cause genetic changes in the recipient cell and infectious viral particles could disseminate in the organism or in the environment and adenoviral vectors can induce a strong immune response in treated patients (Mc Coy et al., Human Gene Therapy 6 (1995), 1553-1560; Yang et al., Immunity 1 (1996), 433-442). Nevertheless, despite these drawbacks, viral vectors are currently the most useful delivery systems because of their efficiency.
- Non-viral delivery systems have been developed which are based on receptor-mediated mechanisms (Perales et al., Eur. J. Biochem. 226 (1994), 255-266; Wagner et al., Advanced Drug Delivery Reviews 14 (1994), 113-135), on polymer-mediated transfection such as polyamidoamine (Haensler and Szoka, Bioconjugate Chem. 4 (1993), 372-379), dendritic polymer (WO 95/24221), polyethylene imine or polypropylene imine (WO 96/02655), polylysine (U.S. Pat. No. 5,595,897 or
FR 2 719 316) or on lipid-mediated transfection (Felgner et al., Nature 337 (1989), 387-388) such as DOTMA (Felgner et al., Proc. Natl. Acad. Sci. USA 84 (1987), 7413-7417), DOGS or Transfectam™ (Behr et al., Proc. Natl. Acad. Sci. USA 86 (1989), 6982-6986), DMRIE or DORIE (Felgner et al., Methods 5 (1993), 67-75), DC-CHOL (Gao and Huang, BBRC 179 (1991), 280-285), DOTAP™ (McLachlan et al., Gene Therapy 2 (1995), 674-622) or Lipofectamine™. These systems present potential advantages with respect to large-scale production, safety, targeting of transfectable cells, low immunogenicity and the capacity to deliver large fragments of DNA. Nevertheless their efficiency in vivo is still limited. Finally, in 1990, Wolff et al. (Science 247 (1990), 1465-1468) have shown that injection of naked RNA or DNA, without a special delivery system, directly into mouse skeletal muscle results in expression of reporter genes within the muscle cells. This technique for transfecting cells offers the advantage of simplicity and experiments have been conducted that support the usefulness of this system for the delivery to the lung (Tsan et al., Am. J. Physiol. 268 (1995), L1052-L1056; Meyer et al., Gene Therapy 2 (1995), 450-460), brain (Schwartz et al., Gene Therapy 3 (1996), 405-411), joints (Evans and Roddins, Gene therapy for arthritis; In Wolff (ed) Gene therapeutics: Methods and Applications of direct Gene Transfer. Birkhaiser. Boston (1990), 320-343), thyroid (Sikes et al., Human Gen. Ther. 5 (1994), 837-844), skin (Raz et al., Proc. Nati. Acad. Sci. USA 91 (1994), 9519-9523) and liver (Hickman et al., Hum. Gene Ther. 5 (1994),1477-1483). - Nevertheless, Davis et al. (Human Gene Therapy 4 (1993), 151-159 and Human Mol. Genet. 4 (1993), 733-740) observed a large variability of expression of naked DNA injected into skeletal muscle in vivo which would be insufficient for the treatment of primary myopathies, for example. The authors propose solutions in order to obtain an improvement of the efficiency of gene transfer by preinjecting muscles with a relatively large volume of hypertonic sucrose or with toxins, for example cardiotoxin isolated from snake, in order to stimulate regeneration of muscles. Nevertheless, these methods, although promising, would not be applicable for human treatment.
- Thus, the available delivery methods are not satisfactory in terms of safety or efficiency for their implementation in in vivo gene therapy.
- Therefore, the technical problem underlying the present invention is the provision of improved methods and means for the delivery of nucleic acid molecules in gene therapy.
- This technical problem is solved by the provision of the embodiments as defined in the claims.
- Thus, the present invention relates to the use of magnesium (Mg2+) for the preparation of a therapeutic composition for transfecting a polynucleotide into a cell in vivo. It was surprisingly found that the specific addition of magnesium when transfecting a polynucleotide into vertebrate tissue leads to a dramatic improvement of the transfection efficiency. Thus, the present invention preferably relates to the use of magnesium (Mg2+) for the preparation of a pharmaceutical composition for an improved transfection of a polynucleotide into a cell. The term “improved transfection” in the scope of the present invention means, in this regard, a more efficient uptake of a polynucleotide by cells when magnesium (Mg2+) is present compared to an introduction performed without magnesium. This can be determined by comparing the amount of the polynucleotide taken up without the use of magnesium and comparing this amount with the amount taken up by the cells when using magnesium under the same experimental conditions. Preferably, the improved transfection can be determined by a higher amount of expression of the polynucleotide transferred into the cells when using magnesium (Mg2+) in comparison to a situation where no magnesium (Mg2+) is used.
- The therapeutic compositions prepared according to the use of the present invention are particularly useful for the delivery of polynucleotides to cells or tissues of a subject in the scope of a gene therapeutic method but are not limited to such use. The term “gene therapy method” is preferably understood as a method for the transfection of a polynucleotide into cells in vivo. “Gene therapy” in particular concerns the case where the gene product is expressed in a target tissue as well as the case where the gene product is excreted, especially into the blood stream.
- In the scope of the present invention the term “transfection” means the transfer of the polynucleotide into a cell wherein the polynucleotide is not associated with viral particles. Thus, transfection is to be distinguished from infection which relates to polynucleotides associated with viral particles.
- Magnesium (Mg2+) has been shown to:
- reduce the interaction of virus with water leading to a decline in the extent of water penetration into the viral capside (Chen et al., Arch. Biochem. Biophys. 342 (1997), 108-116);
- bind to nucleic acids (Rowatt et Williams, J. Inorg. Biochem. 46 (1992), 87-97);
- influence DNase I inactivation by heat treatment (Bickler et al., Biotechniques 13 (1992), 64-6);
- be involved in metabolic functions such as glycolysis, RNA/DNA synthesis or protein synthesis (Gunther, Magnesium 5 (1986), 53-9);
- act as a cofactor for the binding of the C protein to its specific site in DNA (De et al., Biochemistry 37 (1998), 3831-8) or of the EcoRV restriction endonuclease (Thielking et al., Biochemistry 31 (1992), 3727-32).
- Japanese patent application (JO8308573) abstract discloses an in vitro method of introducing a gene into cells by using a virus as vector, prepared in a virus-infection medium which contains serum-free ingredients or divalent metal ions selected from Mg, Ca and Zn combined with a cell culture medium based on amino acids.
- The term “magnesium (Mg2+)” as used herein, means the divalent cation of magnesium. Such a product is commercially available associated with one or several biologically acceptable anions, such as, for example, bisulfite, chromate, fluoride, gluconate, acetate, hydroxide, iodide, methoxide, oxide, phosphate, sulfate, chloride, bromide, etc (see Aldrich catalogue, 1994/1995, for example). According to a preferred embodiment, said magnesium (Mg2+) is associated with chloride (MgCl2).
- In a preferred embodiment the amount of magnesium in the compositions prepared according to the use of the present invention ranges between about 0.1 to about 100 mM, preferably from about 0.1 to about 10 mM of magnesium, and still preferably is 0.5 mM. This concentration may also be adapted by those skilled in the art in particular cases where magnesium concentration can be affected. For example, when the therapeutic composition further comprises chelating agent, such as EDTA, it would be preferable to improve the magnesium concentration in order to compensate for magnesium depletion due to chelation. This can occur when the polynucleotide has been previously prepared in a buffer such as TE (Tris-EDTA).
- In a preferred embodiment the therapeutic composition prepared according to the use of the present invention is in a form for administration into a vertebrate tissue. These tissues include those of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, connective tissue, blood, tumor etc. Cells where the improved transfection of a foreign polynucleotide would be obtained are those found in each of the listed target tissues (muscular cells, airway cells, hematopoïetic cells, etc.). The administration may be made by intradermal, subdermal, intravenous, intramuscular, intranasal, intracerebral, intratracheal, intraarterial, intraperitoneal, intravesical, intrapleural, intracoronary or intratumoral injection, with a syringe or other devices. Transdermal administration is also contemplated, as are inhalation or aerosol administration.
- In a preferred embodiment, the therapeutic composition prepared according to the use is for the introduction into muscle tissue, more preferably, by intramuscular injection routes.
- In another preferred embodiment, the invention provides the use of magnesium for the preparation of a therapeutic composition for improving transfection of a polynucleotide into a cell wherein said therapeutic composition is administered independently from a second administration consisting in administration of a composition containing at least one polynucleotide. According to the present invention, the first administration can be done prior to, concurrently with or subsequent to the second administration, and vice-versa. The therapeutic composition administration and second administration can be performed by different or identical delivery routes (systemic delivery and targeted delivery, or targeted deliveries for example). In a preferred embodiment, each should be done into the same target tissue and most preferably by injection.
- In a further preferred embodiment of the use according to the present invention, the therapeutic composition further comprises at least one polynucleotide. In a particularly preferred embodiment, the polynucleotide which is contained in the composition, contains and is capable of functionally expressing a gene in said cell. The polynucleotide may be a DNA or RNA, single or double stranded, linear or circular, natural or synthetic, modified or not (see U.S. Pat. No. 5,525,711, U.S. Pat. No. 4,711,955 or EP-A 302 175 for modification examples). It may be, inter alia, a genomic DNA, a cDNA, an mRNA, an antisense RNA, a ribosomal RNA, a ribozyme, a transfer RNA or DNA encoding such RNAs. “Polynucleotides” and “nucleic acids” are synonyms with regard to the present invention. The polynucleotide may also be in the form of a plasmid or linear polynucleotide which contains at least one expressible sequence of nucleic acid that can generate a polypeptide, a ribozyme, an antisense RNA or another molecule of interest upon delivery to a cell. The polynucleotide can also be an oligonucleotide which is to be delivered to the cell, e.g., for antisense or ribozyme functions.
- In a particularly preferred embodiment of the invention the polynucleotide is a naked polynucleotide (Wolff et al., Science 247 (1990), 1465-1468) or is a polynucleotide associated or complexed with a polypeptide, with the proviso that when said polypeptide is a viral polypeptide, then said polynucleotide combined with the viral polypeptide does not form infectious viral particles, or with a cationic compound or with any component which can participate in the protection and uptake of the polynucleotide into the cells (see Ledley, Human Gene Therapy 6 (1995), 1129-1144 for a review). Cationic compounds to which the polynucleotide is complexed are preferably cationic lipids, especially those disclosed in WO 98/34910. Both DNA or RNA can be delivered to cells to form therein a polypeptide of interest. Preferably, the polynucleotide present in the therapeutic composition is in the form of plasmid DNA. If the polynucleotide contains the proper genetic information, it will direct the synthesis of relatively large amounts of the encoded polypeptide. When the polynucleotide delivered to the cells encodes an immunizing polypeptide, the use according to the invention can be applied to achieve improved and effective immunity against infectious agents, including intracellular viruses, and also against tumor cells. The genetic informations necessary for expression by a target cell comprise all the elements required for transcription of said DNA into mRNA and for translation of mRNA into polypeptide. Transcriptional promoters suitable for use in various vertebrate systems are well known. For example, suitable promoters include viral promoters like RSV, MPSV, SV40, CMV or 7.5 k, vaccinia promoter, inducible promoters, etc. The polynucleotide can also include intron sequences, targeting sequences, transport sequences, sequences involved in replication or integration. Said sequences have been reported in the literature and can be readily obtained by those skilled in the art. The polynucleotide can also be modified in order to be stabilized with specific components as spermine.
- In general, the concentration of the polynucleotide in the composition is from about 0.1 μg/ml to about 20 mg/ml. According to the invention, the polynucleotide can be homologous or heterologous to the target cells into which it is introduced. Advantageously said polynucleotide encodes all or part of a polypeptide, especially a therapeutic or prophylactic polypeptide. A polypeptide is understood to be any translational product of a polynucleotide regardless of size, and whether glycosylated or not, and includes peptides and proteins. Therapeutic polypeptides include as a primary example those polypeptides that can compensate for defective or deficient proteins in an animal or human organism, or those that act through toxic effects to limit or remove harmful cells from the body. They can also be immunity conferring polypeptides which act as endogenous immunogens to provoke a humoral or cellular response, or both. Examples of polypeptides encoded by the polynucleotide are enzymes, hormones, cytokines, membrane receptors, structural polypeptides, transport polypeptides, adhesines, ligands, transcription factors, traduction factors, replication factors, stabilization factors, antibodies, more especially CFTR, dystrophin, factors VIII or IX, E6 or E7 from HPV, MUC1, BRCA1, interferons, interleukin (IL-2, IL-4, IL-6, IL-7, IL-12, GM-CSF (Granulocyte Macrophage Colony Stimulating Factor), the tk gene from
Herpes Simplex type 1 virus (HSV-1), p53 or VEGF. The polynucleotide can also code for an antibody. In this regard, antibody encompasses whole immunoglobulins of any class, chimeric antibodies and hybrid antibodies with dual or multiple antigen or epitope specificities, and fragments, such as F(ab)2, Fab', Fab including hybrid fragments and anti-idiotypes (U.S. Pat. No. 4,699,880). - In a further preferred embodiment the composition further comprises at least one component selected from the group consisting of chloroquine, protic compounds such as propylene glycol, polyethylene glycol, glycerol, ethanol, 1-methyl L-2-pyrrolidone or derivatives thereof, aprotic compounds such as dimethylsulfoxide (DMSO), diethylsulfoxide, di-n-propylsulfoxide, dimethylsulfone, sulfolane, dimethylformamide, dimethylacetamide, tetramethylurea, acetonitrile or derivatives. Said composition can also comprises at least one component selected from the group consisting of cytokines, especially interleukin-10 (IL-10), and nuclease inhibitors such as, for example, actin G.
- In another preferred embodiment the composition prepared according to the use of the invention can be used in a method for the therapeutic treatment of humans or animals. In this particular case, the composition may also comprise a pharmaceutically acceptable injectable carrier (for examples, see Remington's Pharmaceutical Sciences, 16th ed. 1980, Mack Publishing Co). The carrier is preferably isotonic, hypotonic or weakly hypertonic and has a relatively low ionic strength, such as provided by a sucrose solution. Furthermore, it may contain any relevant solvents, aqueous or partly aqueous liquid carriers comprising sterile, pyrogen-free water, dispersion media, coatings, and equivalents, or diluents (e.g;, Tris-HCl, acetate, phosphate), emulsifiers, solubilizers or adjuvants. The pH of the pharmaceutical preparation is suitably adjusted and buffered in order to be useful in in vivo applications.
- In another aspect the present invention also relates to a process for transfecting a polynucleotide into cells wherein said process comprises contacting said cells with a composition prepared according to the use of the invention before, simultaneously or after contacting them with the polynucleotide. This process may be applied by direct administration of said composition to cells of the animal in vivo. According to the practice of the invention, targeted “cells” and “in vivo administration route” are defined as above described.
- Preferably, muscle is used as a site for the delivery and expression of a polynucleotide in a number of therapeutic applications because animals have a proportionately large muscle mass which is conveniently accessed by direct injection through the skin. Accordingly, in a preferred case, the invention concerns a process for introducing a polynucleotide, preferably in naked form, into muscle cells in vivo, comprising the steps of administering in vivo at least a polynucleotide and magnesium , preferably intramuscularly, whereby the polynucleotide is introduced into muscle cells of the tissue. The polynucleotide may encode a therapeutic polypeptide that is expressed by the muscle cells and eventually secreted into the blood stream after the contacting step to provide therapy to the vertebrate. Similarly, it may encode an immunogenic polypeptide that is expressed by the muscle cells after the contacting step and which generates an immune response, thereby immunizing the vertebrate. One important aspect of the invention is a process for the treatment of muscular dystrophy wherein said polynucleotide operatively codes for dystrophin. Preferably, the composition is introduced into the muscle tissue.
- Finally, the present invention relates to the use of Magnesium (Mg2+) for improving transfection of a polynucleotide into a cell.
- The invention has been described in an illustrative manner, and it is to be understood that the terminology which has been used is intended to be in the nature of words of description rather than of limitation. Obviously, many modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that within the scope of the claims, the invention may be practiced otherwise than as specifically described.
- FIG. 1: shows the opposing effects of CaCl2 and MgCl2 on intramuscular transfection of pTG11033. Luciferase activity of mouse right and left tibialis anterior muscles measured 7 days after injection with 25 μg plasmid added with NaCl 0.9% buffer (Control, NaCl) or with either 0.1 to 100 mM of CaCl2 or 100 mM MgCl2. Bars are means of RLU (Relative Light Unit) per minute per mg protein +/− s.e.m. of 6_determinations.
- FIGS. 2 and 3: show the MgCl2 dose-effect on intramuscular transfer of the luciferase-plasmid (pTG11033). Bars are means of RLU per minute per mg protein +/− s.e.m of 6 determinations. Luciferase activity was measured 7 days after injection of 25 μg plasmid into C57BL/10 mice (4 mice per group) added with either NaCl 0.9% (empty bars) or different concentrations of MgCl2 (black bars).
- The following materials and methods are used in the examples.
- 1. Intramuscular Administration of Plasmid/divalent Ion Composition
- Plasmid DNA (pTG11033: CMV promoter, β-globin intron, luciferase cassette—WO 98/34910) was prepared according to Bischoff et al., Analytical Biochemistry 254 (1997), 69-81. Prior to intramuscular injection the tested molecules were mixed with the plasmid DNA preparation. 25 μg of plasmid DNA were injected per muscle into 5 to 10 week-old C57BL/10 mice. The 2 tibialis anterior (right and left) muscles were injected (each muscle was considered as a sample). Furthermore, for each condition, both the lowest and highest luciferase acitvity values were omitted, which means number of sample per condition =(2×number of mice per condition)−2.
- 2. Muscle Biopsies and Luciferase Measurement
- One week after injection of the composition, the mice were killed and the tibialis anterior muscles were retrieved and frozen.
- Luciferase activity was quantified on whole muscle extracts using a conventional measurement kit (Luciferase Assay System, Promega). Briefly, muscles were ground separately and diluted in 200 μl of reporter lysis buffer (Promega). 10 μl-samples were placed in 96 well-plates and mixed with 100 μl of substrate. Luciferase activity was expressed as number of RLU emitted per minute, per mg of protein.
- 3. Protein Determination
- Protein was measured on 10 μl samples using a VCA Protein Assay kit (Pierce).
- In this example, the stock solution of plasmid pTG11033 was prepared in TE buffer (
Tris 10 mM-EDTA 1 mM) at a nucleic acid concentration of 1 μg/μl. - Stock solutions of CaCl2 and MgCl2 were prepared in water at a concentration of 1 M. Four C57BI/10 mice were injected per condition into the right and left tibialis anterior muscle with different compositions comprising pTG11033 (25 μg/muscle) and various concentrations of calcium chloride (CaCl2; 100, 10, 1, 0.1 mM) or magnesium chloride (MgCl2; 100 mM). The control experiment is performed according to the same condition except that no divalent ion is added and that 5 μl of NaCl 0.9% is added. The injected volume was 30 μl.
- The results are presented in FIG. 1. They show that addition of CaCl2 leads to a dramatic inhibition of luciferase activity of the injected muscles (from 3 to 100 fold drop depending on the final concentration of CaCl2) even at the lowest concentration tested (0.1 mM). Conversely, MgCl2 allowed an increased luciferase activity in the injected muscles (around 3 times in the present example).
- In this example, the plasmid pTG11033 was prepared in NaCl 0.9% and stocked at 1 μg/μl. Serial dilution of MgCl2 solution were prepared in NaCl 0.9% and added to the stock pTG11033 in a final volume of 30 μl. The control contained the same quantity of the plasmid added with 5 μl of NaCl 0.9%. Ionic strength of MgCl2 solutions was balanced with appropriate volumes of water according to methods well known to the person skilled in the art.
- As previously described, four mice were injected per condition.
- The results are presented in FIG. 2. They show that MgCl2 has an influence on luciferase activity of the injected muscles. The lowest dose (0.1 mM) of MgCl2 had no effect on the injected muscle luciferase activity, wherease luciferase activity was higher in muscles injected in the presence of 1 mM MgCl2, similar to the control when 10 mM MgCl2 was used, and strongly inhibited at higher concentrations.
- A more precise range of concentrations of MgCl2 (0.1, 0.5, 1, 2, 5, 10 mM) was evaluated using the same conditions as described for Example 2. It was found that the optimal concentration was 0.5 mM when a preparation of plasmid pTG11033 in 0.9% NaCl was used.
Claims (21)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/108,263 US6881724B2 (en) | 1998-09-30 | 2002-03-28 | Use of magnesium (Mg2+) for the preparation of a therapeutic composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98402424.0 | 1998-09-30 | ||
EP98402424A EP0998945A1 (en) | 1998-09-30 | 1998-09-30 | Use of magnesium (Mg2+) for the enhancement of gene delivery in gene therapy |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/108,263 Continuation US6881724B2 (en) | 1998-09-30 | 2002-03-28 | Use of magnesium (Mg2+) for the preparation of a therapeutic composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020019357A1 true US20020019357A1 (en) | 2002-02-14 |
Family
ID=8235506
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/408,947 Abandoned US20020019357A1 (en) | 1998-09-30 | 1999-09-30 | Use of magnesium (mg2+) for the preparation of a therapeutic composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy |
US10/108,263 Expired - Lifetime US6881724B2 (en) | 1998-09-30 | 2002-03-28 | Use of magnesium (Mg2+) for the preparation of a therapeutic composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/108,263 Expired - Lifetime US6881724B2 (en) | 1998-09-30 | 2002-03-28 | Use of magnesium (Mg2+) for the preparation of a therapeutic composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy |
Country Status (10)
Country | Link |
---|---|
US (2) | US20020019357A1 (en) |
EP (2) | EP0998945A1 (en) |
JP (1) | JP5172054B2 (en) |
AT (1) | ATE243531T1 (en) |
AU (1) | AU767294B2 (en) |
CA (1) | CA2284399C (en) |
DE (1) | DE69909041T2 (en) |
DK (1) | DK1004320T3 (en) |
ES (1) | ES2201611T3 (en) |
PT (1) | PT1004320E (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005007744A1 (en) * | 2004-06-24 | 2006-01-19 | Shf Communication Technologies Ag | Planetary gear, has eccentrically arranged pinion gears to control planetary gear, where controlled moment of energy converters is applied on each pinion gear, and converter is arranged in parallel to cone shaped shell |
US20100075010A1 (en) * | 2008-09-23 | 2010-03-25 | Givaudan S.A. | Flavour Compositions |
WO2019222666A1 (en) * | 2018-05-17 | 2019-11-21 | University Of Florida Research Foundation, Incorporated | Methods and compositions for using metal elements in aav gene therapy |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1278551A2 (en) * | 2000-04-21 | 2003-01-29 | Vical Incorporated | Compositions and methods for (in vivo) delivery of polynucleotide-based therapeutics |
EP1249244A1 (en) * | 2001-04-13 | 2002-10-16 | Universiteit Gent | Therapeutic compositions for the treatment of a disease modulated by the G-actin / F-actin equilibrium, especially a respiratory tract disease |
EP1270733A1 (en) * | 2001-06-21 | 2003-01-02 | Ecole Polytechnique Federale De Lausanne | Method for introducing a nucleic acid into a eukaryotic cell |
WO2003000908A1 (en) * | 2001-06-21 | 2003-01-03 | Ecole Polytechnique Federale De Lausanne | A method for introducing a nucleic acid into a eukaryotic cell |
WO2004075924A1 (en) * | 2003-01-17 | 2004-09-10 | Japan Genome Solutions, Inc. | Gene transfer promoter and gene tansfer composition containing the same |
CA2531773A1 (en) | 2003-07-21 | 2005-02-17 | Transgene S.A. | Novel multifunctional cytokines |
WO2010105135A1 (en) * | 2009-03-13 | 2010-09-16 | Tufts University | Methods, apparatuses, and kits for introducing genetic material into living cells |
JP6430949B2 (en) | 2012-10-23 | 2018-11-28 | エモリー ユニバーシティ | Conjugates, compositions, and related methods of GM-CSF and IL-4 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60188069A (en) * | 1984-03-08 | 1985-09-25 | Nakano Vinegar Co Ltd | Transduction of cyclic dna into acetobacter |
US4798789A (en) * | 1984-10-05 | 1989-01-17 | Dnax Research Institute Of Molecular And Cellular Biology, Inc. | cDNA clones coding for polypeptides exhibiting murine interleukin-2 activity |
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5693622A (en) * | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
US5593972A (en) * | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
FR2710074B1 (en) * | 1993-09-15 | 1995-12-08 | Rhone Poulenc Rorer Sa | GRB3-3 gene, its variants and their uses. |
US5844107A (en) * | 1994-03-23 | 1998-12-01 | Case Western Reserve University | Compacted nucleic acids and their delivery to cells |
FR2724665B1 (en) * | 1994-09-16 | 1996-12-20 | Rhone Poulenc Rorer Sa | PROCESS FOR PRODUCING RECOMBINANT PROTEINS, PLASMIDS AND MODIFIED CELLS |
JPH08308573A (en) * | 1995-05-19 | 1996-11-26 | Ube Ind Ltd | Transduction of gene to cell and virus-infected medium used therefor |
AU7142796A (en) * | 1995-10-02 | 1997-04-28 | Erasmus University Rotterdam | Diagnosis method and reagents |
US5994316A (en) * | 1996-02-21 | 1999-11-30 | The Immune Response Corporation | Method of preparing polynucleotide-carrier complexes for delivery to cells |
US6544523B1 (en) * | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
US5830698A (en) * | 1997-03-14 | 1998-11-03 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
FR2763958A1 (en) * | 1997-05-29 | 1998-12-04 | Transgene Sa | COMBINATION PRODUCT COMBINING A NUCLEIC ACID WITH A SUBSTANCE DISORGANIZING THE EXTRACELLULAR MATRIX FOR GENE THERAPY |
AU752658B2 (en) * | 1998-05-06 | 2002-09-26 | Association Francaise Contre Les Myopathies | Use of a nuclease inhibitor or interleukin-10 (IL-10) for the preparation of a therapeutic composition for improving transfection of a polynucleotide into a cell and compositions useful in gene therapy |
-
1998
- 1998-09-30 EP EP98402424A patent/EP0998945A1/en not_active Withdrawn
-
1999
- 1999-09-29 CA CA2284399A patent/CA2284399C/en not_active Expired - Fee Related
- 1999-09-29 AU AU51397/99A patent/AU767294B2/en not_active Ceased
- 1999-09-30 PT PT99119057T patent/PT1004320E/en unknown
- 1999-09-30 AT AT99119057T patent/ATE243531T1/en not_active IP Right Cessation
- 1999-09-30 JP JP27850599A patent/JP5172054B2/en not_active Expired - Fee Related
- 1999-09-30 DK DK99119057T patent/DK1004320T3/en active
- 1999-09-30 ES ES99119057T patent/ES2201611T3/en not_active Expired - Lifetime
- 1999-09-30 EP EP99119057A patent/EP1004320B1/en not_active Expired - Lifetime
- 1999-09-30 DE DE69909041T patent/DE69909041T2/en not_active Expired - Lifetime
- 1999-09-30 US US09/408,947 patent/US20020019357A1/en not_active Abandoned
-
2002
- 2002-03-28 US US10/108,263 patent/US6881724B2/en not_active Expired - Lifetime
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005007744A1 (en) * | 2004-06-24 | 2006-01-19 | Shf Communication Technologies Ag | Planetary gear, has eccentrically arranged pinion gears to control planetary gear, where controlled moment of energy converters is applied on each pinion gear, and converter is arranged in parallel to cone shaped shell |
US20100075010A1 (en) * | 2008-09-23 | 2010-03-25 | Givaudan S.A. | Flavour Compositions |
WO2019222666A1 (en) * | 2018-05-17 | 2019-11-21 | University Of Florida Research Foundation, Incorporated | Methods and compositions for using metal elements in aav gene therapy |
Also Published As
Publication number | Publication date |
---|---|
US6881724B2 (en) | 2005-04-19 |
AU767294B2 (en) | 2003-11-06 |
EP0998945A1 (en) | 2000-05-10 |
ES2201611T3 (en) | 2004-03-16 |
CA2284399C (en) | 2011-01-18 |
DE69909041D1 (en) | 2003-07-31 |
JP5172054B2 (en) | 2013-03-27 |
EP1004320B1 (en) | 2003-06-25 |
DK1004320T3 (en) | 2003-09-15 |
US20020156045A1 (en) | 2002-10-24 |
PT1004320E (en) | 2003-10-31 |
ATE243531T1 (en) | 2003-07-15 |
DE69909041T2 (en) | 2004-04-01 |
EP1004320A1 (en) | 2000-05-31 |
AU5139799A (en) | 2000-04-06 |
JP2000143549A (en) | 2000-05-23 |
CA2284399A1 (en) | 2000-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2242035C (en) | Compositions useful for transferring therapeutically active substances into a target cell, and their use in gene therapy | |
US6881724B2 (en) | Use of magnesium (Mg2+) for the preparation of a therapeutic composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy | |
US6723708B2 (en) | Use of lithium (Li+) for the preparation of a composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy | |
JP2001270840A (en) | Treatment of immunological disease | |
US20050152959A1 (en) | Use of a lysolipid for the preparation of a composition for transfection of a polynucleotide into a cell | |
EP0987029B1 (en) | Use of a catonic polymer for the preparation of a complex with nucleic acid and related compositions | |
JP2005513073A6 (en) | Use of lysolipids for the manufacture of compositions for transfection of polynucleotides into cells | |
EP1052288A1 (en) | Complex for transferring an anionic substance of interest into a cell | |
AU770607B2 (en) | Complex for transferring an anionic substance of interest into a cell | |
EP0967289A1 (en) | Improvements in gene therapy using compositions comprising a polynucleotide and a nuclease inhibitor | |
WO2000037664A1 (en) | Method for preparing suspension of stable posiplexes | |
EP1006197A1 (en) | Use of an immuno complex for the preparation of a therapeutic composition useful for transfecting a polynucleotide into macropinocyte cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: TRANSGENE N.V., FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BRAUN, SERGE;REEL/FRAME:010450/0714 Effective date: 19991201 |
|
AS | Assignment |
Owner name: TRANSGENE S.A., FRANCE Free format text: CORRECTIVE ASSIGNMENT TO ADD THE SECOND ASSIGNEE TO THE PREVIOUSLY RECORDED DOCUMENT ON REEL 010450 FRAME 0714;ASSIGNOR:BRAUN, SERGE;REEL/FRAME:010931/0754 Effective date: 20000505 Owner name: ASSOCIATION FRANCAISE CONTRE LES MYOPATHIES, FRANC Free format text: CORRECTIVE ASSIGNMENT TO ADD THE SECOND ASSIGNEE TO THE PREVIOUSLY RECORDED DOCUMENT ON REEL 010450 FRAME 0714;ASSIGNOR:BRAUN, SERGE;REEL/FRAME:010931/0754 Effective date: 20000505 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |